<DOC>
	<DOC>NCT02371096</DOC>
	<brief_summary>Pharmacokinetic properties, efficacy, safety and tolerability of RGB-03 and MabThera will be compared in patients suffering from Rheumatoid Arthritis.</brief_summary>
	<brief_title>Comparative Pharmacokinetic Trial of RGB-03 and MabThera</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Active Rheumatoid Arthritis Inadequate response or intolerance to other DMARDs and antiTNFs Treatment with Methotrexate Previous treatment with rituximab Patients with systemic manifestations of rheumatoid arthritis Patients seropositive for HIV, HCV, HBV Female patients nursing Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>